Press and Announcements

Praetego’s progress is routinely updated as we strive to enter clinical trials.
Please check back frequently for news, announcements, and events.


Praetego awarded $2.5M from NIA to continue Alzheimer’s work

October 4, 2022

Praetego Inc, a pharmaceutical company committed to protecting patients from neurodegenerative diseases related to aging, is pleased to announce a $2.5M STTR award from the National Institute of Aging (NIA). The Phase 2 award advances Praetego’s lead candidate, PTG-630, against Alzheimer’s disease (AD).


Praetego Wins RESI Longevity Innovator’s Pitch Challenge

September 30, 2021

Praetego wins Innovator’s Pitch Challenge at RESI Longevity


Praetego Receives Third Grant from the NIH

June 1, 2021

Praetego Inc, a preclinical stage pharmaceutical company developing novel candidates against chronic diseases of aging, is pleased to announce an award of a $458K grant to study the Amadorin candidates for the treatment of Alzheimer’s Disease.

View press release here.